Immex (Loperamide Hydrochloride)

Loperamide Hydrochloride acts as a peripheral μ‑opioid receptor agonist in the gut. By activating these receptors it inhibits the release of acetylcholine and prostaglandins, decreasing smooth‑muscle activity and peristalsis. The result is reduced intestinal motility and increased absorption of water and electrolytes, leading to firmer stools.

The appropriate dose of Immex is determined by the prescribing healthcare professional based on the individual’s condition, age, and response to therapy. Patients should follow the prescriber’s instructions and the product labeling, and should not adjust the dose without medical guidance.

Safety data for Loperamide Hydrochloride in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their healthcare provider.

To request Immex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any required import documentation.

The most common alternative to Loperamide is diphenoxylate combined with atropine. Both reduce intestinal motility, but diphenoxylate has central opioid activity that can cause sedation, whereas Loperamide remains largely peripheral, offering a lower risk of central opioid effects. Choice depends on clinical judgment, patient tolerance and regulatory considerations.

Immex should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments to maintain its stability.

Immex is taken orally. The tablet should be swallowed whole with a glass of water. It may be taken with or without food, but patients should follow the dosing schedule prescribed by their healthcare professional.

Serious adverse events include severe constipation or intestinal obstruction, toxic megacolon, allergic reactions such as rash or swelling, and cardiac arrhythmias like QT‑interval prolongation. Patients should seek immediate medical attention if they experience abdominal pain, vomiting, faintness, or signs of an allergic reaction.

Immex should not be used in children younger than 2 years, in patients with known hypersensitivity to loperamide, or in individuals with bacterial enteritis, colitis caused by Clostridioides difficile, or acute dysentery. Caution is also advised for patients with severe hepatic impairment or those taking interacting medications.